For research use only. Not for therapeutic Use.
N. N-dipropyrldopamine is a potent inhibitor of glutamate release and has anticancer activity. The increase of glutamate secretion leads to cancer-induced bone pain (CIBP). N. N-dipropyrldopamine plays an analgesic role in CIBP[1].
N,N-dipropyldopamine (10-200 μM, 48 h) inhibits cancer cells growth of MDA-MB-231, MCF-7 and Mat-Ly-Lu, with IC50 values of 25.45, 26.3, 28.45 μM, respectively [1].
Catalog Number | I033403 |
CAS Number | 65273-66-7 |
Synonyms | 4-[2-(dipropylamino)ethyl]benzene-1,2-diol;hydrobromide |
Molecular Formula | C14H24BrNO2 |
Purity | ≥95% |
InChI | InChI=1S/C14H23NO2.BrH/c1-3-8-15(9-4-2)10-7-12-5-6-13(16)14(17)11-12;/h5-6,11,16-17H,3-4,7-10H2,1-2H3;1H |
InChIKey | QAXMCYJNFHCJFB-UHFFFAOYSA-N |
SMILES | CCCN(CCC)CCC1=CC(=C(C=C1)O)O.Br |
Reference | [1]. Fazzari J, et al. Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain. Sci Rep. 2015 Feb 11;5:8380. |